Clinical Challenges: Beyond CDK4/6 Inhibition in Advanced HR-Positive Breast Cancer
The emergence of CDK4/6 inhibitors has reshaped the therapeutic landscape for advanced hormone receptor (HR)-positive breast cancer, extending progression-free survival (PFS) and in some cases overall survival (OS) when combined with first-line endocrine therapy. Unfortunately, most patients eventually progress, and the next step after CDK4/6 inhibition is perhaps “the hottest topic that all of us […]